Open Access<p>Enhancing Anti-Tumor Activity of Sorafenib Mesoporous Silica Nanomatrix in Metastatic Breast Tumor and Hepatocellular Carcinoma via the Co-Administration with Flufenamic Acid</p>
Author(s) -
Zhuoyue Li,
Yi-Fan Yin,
Yang Guo,
Hui Li,
Meiqi Xu,
Man Liu,
Jingru Wang,
Zhen-Han Feng,
Xiao-Chuan Duan,
Shuang Zhang,
Shuaiqiang Zhang,
Guangxue Wang,
Ai Ho Liao,
Shumin Wang,
Xuan Zhang
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s240436
Subject(s) - flufenamic acid , cancer research , in vivo , sorafenib , chemistry , hepatocellular carcinoma , cytotoxicity , pharmacology , medicine , in vitro , biology , biochemistry , microbiology and biotechnology
Because tumor-associated inflammation is a hallmark of cancer treatment, in the present study, sorafenib mesoporous silica nanomatrix (MSNM@SFN) co-administrated with flufenamic acid (FFA, a non-steroidal anti-inflammatory drug (NSAID)) was investigated to enhance the anti-tumor activity of MSNM@SFN.